Seattle biotech just turned the volume up, and the bass line is Kinea Bio. Founded in 2020 out of the University of Washington’s research grind, this team is chasing rare neuromuscular diseases most people can’t pronounce but families can’t escape. On September 23, 2025, they secured a milestone-based commitment of up to $1.1 million from the Jain Foundation to push their lead program, KNA-155, toward IND-enabling studies in dysferlinopathy. This isn’t another spray-and-pray round. It’s a targeted bet from a foundation created by Ajit Jain that exists solely to crack this exact disease. Precision funding meets precision science.
Kinea Bio’s leadership reads like the biotech version of a heavyweight title card. Chief Executive Officer Martin K. (Casey) Childers, DO, PhD, who cut his teeth at AskBio and the University of Washington, knows the clinical and business trenches. Chief Scientific Advisor Jeffrey Chamberlain, PhD, isn’t a figurehead, he’s president of the American Society of Gene and Cell Therapy and has the hardware to prove decades of impact. Chief Operating Officer Seung Wook Oh, PhD, is driving operations with the discipline of someone who’s lived this science, while Chief Financial Officer Michael Cho, JD, runs strategy and capital like a chess player who already knows the endgame. Together, they’re building a company designed to solve problems no one else has touched.
Their technology platform is the kind of innovation that forces the industry to take notice. SIMPLI-GT stitches together protein fragments too large for standard AAV delivery, unlocking full-length therapeutic proteins that were off-limits until now. MyoXpress expression cassettes fine-tune gene expression specifically in skeletal and cardiac muscle, reducing noise in the wrong tissues. Their engineered myotropic capsids bring muscle-targeted delivery to the forefront, while BioDrone nanovesicles create a path to repeat dosing without setting off immune alarms. Each piece isn’t a gimmick, it’s a necessary answer to the biggest roadblocks in genetic medicine.
The Jain Foundation’s money will bankroll toxicology, biodistribution, and dose-finding studies that open the path to first-in-human trials. At the same time, Kinea Bio locked down a non-exclusive license with Solid Biosciences for AAV-SLB101, a capsid that’s already shown enhanced muscle tropism and reduced liver uptake. That’s not just a partnership, it’s a statement that they’re not reinventing every wheel when they can borrow one that already rolls smoother.
Stack the numbers: $500,000 from PPMD, $2.26 million in NIH SBIR grants, competitive awards from UW and disease foundations, and now this milestone-based $1.1 million commitment. Kinea Bio has pulled in about $2.76 million in non-dilutive funding, building discipline into their growth. No hype, no shortcuts, just strategic capital aligned with execution.
Seattle has birthed plenty of biotech plays, but this one feels like it’s swinging for more than headlines. Kinea Bio isn’t trying to be everything for everyone. They’re proving that with the right science, team, and partners, even the toughest diseases can be cornered. The question isn’t whether they’ll get to the clinic, it’s how many walls they’ll tear down once they’re there.
